Teriparatide evidence, regulatory status, intended use, known risks, and limitations.
Regulatory status
FDA-approved for specific osteoporosis indications
Quick verdict
An evidence-backed prescription option for its specific FDA-approved indication. Individual decisions require a licensed clinician.
At a glance
Primary use: Osteoporosis in certain patients at high risk for fracture. Evidence strength: Strong — FDA-reviewed clinical program. Prescription treatment and clinician supervision are required.
What it is
Teriparatide is a parathyroid hormone analog used for specific osteoporosis populations at high fracture risk.
What it’s used for
Osteoporosis in certain patients at high risk for fracture
How it works
Mechanism and pharmacology are described in the current FDA prescribing information; this review does not provide dosing instructions.
Clinical evidence
Strong — FDA-reviewed clinical program. Public claims on this page are limited to the cited regulatory and clinical evidence.
FDA / Regulatory status
FDA-approved for specific osteoporosis indications
Administration
Once-daily subcutaneous injection. Prescription required and clinician-directed; specialty-pharmacy steps or prior authorization may apply. Coverage and patient cost vary. Lilly documents eligibility-limited Forteo savings and patient-assistance programs. FDA records confirm generic teriparatide approvals; actual pharmacy availability should be checked.
Potential benefits
FDA-reviewed evidence supports product-specific benefits for labeled indications.
Known risks & side effects
Labeling discusses osteosarcoma findings in rats, hypercalcemia, urolithiasis risk, orthostatic hypotension, and hypersensitivity.
Contraindications / Important warnings
Labeling discusses osteosarcoma findings in rats, hypercalcemia, urolithiasis risk, orthostatic hypotension, and hypersensitivity.
Who it may be appropriate for
Potentially appropriate only for patients who meet product-specific labeled criteria after clinician assessment.
Evidence gaps
Eligibility and monitoring require clinician assessment.
Alternatives
Review established options for the relevant goal and discuss clinically appropriate alternatives with a licensed professional.
Score breakdown
Editorial score 8.6/10 — Clinical Evidence 9; Regulatory Status 10; Effectiveness Evidence 8.5; Safety / Known Risks 7.5; Access & Convenience 7; Cost Transparency 7. Weighted using the published methodology.
Final verdict
A legitimate prescription therapy for specific approved uses, with important product-specific risks and limitations.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.